共 243 条
[1]
Brahmer J(2016)Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer N Engl J Med 373 123-135
[2]
Reckamp KL(2015)Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer N Engl J Med 373 1627-1639
[3]
Baas P(2015)Nivolumab in previously untreated melanoma without BRAF mutation N Engl J Med 372 320-330
[4]
Crinò L(2015)Nivolumab versus everolimus in advanced renal-cell carcinoma N Engl J Med 373 1803-1813
[5]
Eberhardt WE(2016)Nivolumab for recurrent squamous-cell carcinoma of the head and neck N Engl J Med 375 1856-1867
[6]
Poddubskaya E(2015)PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma New Engl J Med 372 311-319
[7]
Antonia S(2016)Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial Lancet Oncol 17 1283-1294
[8]
Pluzanski A(2019)Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced NSCLC: CheckMate 078 randomized phase III clinical trial J Thorac Oncol 14 867-875
[9]
Vokes EE(2019)Correlation between serum adenosine deaminase activity and efficacy of anti-programmed cell death-1 antibody Lung Cancer 133 4-9
[10]
Holgado E(2017)iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics Lancet Oncol 18 e143-e152